Click here to close
Hello! We notice that you are using Internet Explorer, which is not supported by Xenbase and may cause the site to display incorrectly.
We suggest using a current version of Chrome,
FireFox, or Safari.
EMBO J
1990 May 01;95:1595-602. doi: 10.1002/j.1460-2075.1990.tb08279.x.
Show Gene links
Show Anatomy links
Activating mutations in p53 produce a common conformational effect. A monoclonal antibody specific for the mutant form.
Gannon JV
,
Greaves R
,
Iggo R
,
Lane DP
.
???displayArticle.abstract???
Point mutations in the p53 gene are the most frequently identified genetic change in human cancer. They convert murine p53 from a tumour suppressor gene into a dominant transforming oncogene able to immortalize primary cells and bring about full transformation in combination with an activated ras gene. In both the human and murine systems the mutations lie in regions of p53 conserved from man to Xenopus. We have developed a monoclonal antibody to p53 designated PAb240 which does not immunoprecipitate wild type p53. A series of different p53 mutants all react more strongly with PAb240 than with PAb246. The PAb240 reactive form of p53 cannot bind to SV40 large T antigen but does bind to HSP70. In contrast, the PAb246 form binds to T antigen but not to HSP70. PAb240 recognizes all forms of p53 when they are denatured. It reacts with all mammalian p53 and chicken p53 in immunoblots. We propose that immunoprecipitation of p53 by PAb240 is diagnostic of mutation in both murine and human systems and suggest that the different point mutations which convert p53 from a recessive to a dominant oncogene exert a common conformational effect on the protein. This conformational change abolishes T antigen binding and promotes self-oligomerization. These results are consistent with a dominant negative model where mutant p53 protein binds to and neutralizes the activity of p53 in the wild type conformation.
Baker,
Chromosome 17 deletions and p53 gene mutations in colorectal carcinomas.
1989, Pubmed
Baker,
Chromosome 17 deletions and p53 gene mutations in colorectal carcinomas.
1989,
Pubmed
Banks,
Isolation of human-p53-specific monoclonal antibodies and their use in the studies of human p53 expression.
1986,
Pubmed
Ben David,
Inactivation of the p53 oncogene by internal deletion or retroviral integration in erythroleukemic cell lines induced by Friend leukemia virus.
1988,
Pubmed
Braithwaite,
Mouse p53 inhibits SV40 origin-dependent DNA replication.
,
Pubmed
Cattoretti,
P53 expression in breast cancer.
1988,
Pubmed
Eliyahu,
Participation of p53 cellular tumour antigen in transformation of normal embryonic cells.
,
Pubmed
Eliyahu,
Wild-type p53 can inhibit oncogene-mediated focus formation.
1989,
Pubmed
Finlay,
Activating mutations for transformation by p53 produce a gene product that forms an hsc70-p53 complex with an altered half-life.
1988,
Pubmed
Finlay,
The p53 proto-oncogene can act as a suppressor of transformation.
1989,
Pubmed
Gannon,
p53 and DNA polymerase alpha compete for binding to SV40 T antigen.
,
Pubmed
Harlow,
Monoclonal antibodies specific for simian virus 40 tumor antigens.
1981,
Pubmed
Hinds,
Mutation is required to activate the p53 gene for cooperation with the ras oncogene and transformation.
1989,
Pubmed
Hinds,
Immunological evidence for the association of p53 with a heat shock protein, hsc70, in p53-plus-ras-transformed cell lines.
1987,
Pubmed
James,
Mitotic recombination of chromosome 17 in astrocytomas.
1989,
Pubmed
Jenkins,
Cellular immortalization by a cDNA clone encoding the transformation-associated phosphoprotein p53.
,
Pubmed
Lacy,
A modified method to induce immune polyclonal ascites fluid in BALB/c mice using Sp2/0-Ag14 cells.
1986,
Pubmed
Lane,
T antigen is bound to a host protein in SV40-transformed cells.
1979,
Pubmed
Linzer,
Characterization of a 54K dalton cellular SV40 tumor antigen present in SV40-transformed cells and uninfected embryonal carcinoma cells.
1979,
Pubmed
Mackay,
Allele loss on short arm of chromosome 17 in breast cancers.
1988,
Pubmed
Nigro,
Mutations in the p53 gene occur in diverse human tumour types.
1989,
Pubmed
Parada,
Cooperation between gene encoding p53 tumour antigen and ras in cellular transformation.
,
Pubmed
Rovinski,
Immortalization of rat embryo fibroblasts by the cellular p53 oncogene.
1988,
Pubmed
Simanis,
An immunoaffinity purification procedure for SV40 large T antigen.
1985,
Pubmed
Soussi,
Cloning and characterization of a cDNA from Xenopus laevis coding for a protein homologous to human and murine p53.
1987,
Pubmed
,
Xenbase
Stürzbecher,
Mouse p53 blocks SV40 DNA replication in vitro and downregulates T antigen DNA helicase activity.
1988,
Pubmed
Stürzbecher,
Characterization of mutant p53-hsp72/73 protein-protein complexes by transient expression in monkey COS cells.
1988,
Pubmed
Takahashi,
p53: a frequent target for genetic abnormalities in lung cancer.
1989,
Pubmed
Thomas,
Characterization of human p53 antigens employing primate specific monoclonal antibodies.
1983,
Pubmed
Wade-Evans,
Precise epitope mapping of the murine transformation-associated protein, p53.
1985,
Pubmed
Wang,
The murine p53 protein blocks replication of SV40 DNA in vitro by inhibiting the initiation functions of SV40 large T antigen.
1989,
Pubmed
Welch,
Rapid purification of mammalian 70,000-dalton stress proteins: affinity of the proteins for nucleotides.
1985,
Pubmed
Yewdell,
Monoclonal antibody analysis of p53 expression in normal and transformed cells.
1986,
Pubmed
Yokota,
Loss of heterozygosity on chromosomes 3, 13, and 17 in small-cell carcinoma and on chromosome 3 in adenocarcinoma of the lung.
1987,
Pubmed
van den Berg,
Expression of the nuclear oncogene p53 in colon tumours.
1989,
Pubmed